The Latin America, Middle East and Africa Anxiety Disorders And Depression Treatment Market is projected to witness market growth of 5.8% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Anxiety Disorders And Depression Treatment Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $316.1 million by 2031. The Argentina market is showcasing a CAGR of 6.5% during 2024-2031. Additionally, the UAE market would register a CAGR of 5.1% during 2024-2031.
Innovations in the treatment of anxiety disorders and depression are continually evolving to address the complex nature of these conditions. Advances in technology, research, and therapeutic approaches are driving significant improvements in how these mental health issues are managed.
Moreover, medications like ketamine and its derivative ketamine have emerged as rapid-acting antidepressants, offering relief from severe depression within hours or days rather than weeks. These treatments are particularly beneficial for individuals with treatment-resistant depression.
With growing mental health issues among children, there’s a rising demand for specialized treatment services. This includes increased utilization of paediatric mental health professionals, child psychologists, and psychiatrists in the UAE. Depressive symptoms are experienced by approximately 17% to 22% of young people in the United Arab Emirates, as indicated by the International Health Policies. Depression and anxiety symptoms are reported by up to one-third of children with chronic disorders.
Based on Indication, the market is segmented into Anxiety and Depression. Based on Drugs, the market is segmented into Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Anxiety Disorders And Depression Treatment Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $316.1 million by 2031. The Argentina market is showcasing a CAGR of 6.5% during 2024-2031. Additionally, the UAE market would register a CAGR of 5.1% during 2024-2031.
Innovations in the treatment of anxiety disorders and depression are continually evolving to address the complex nature of these conditions. Advances in technology, research, and therapeutic approaches are driving significant improvements in how these mental health issues are managed.
Moreover, medications like ketamine and its derivative ketamine have emerged as rapid-acting antidepressants, offering relief from severe depression within hours or days rather than weeks. These treatments are particularly beneficial for individuals with treatment-resistant depression.
With growing mental health issues among children, there’s a rising demand for specialized treatment services. This includes increased utilization of paediatric mental health professionals, child psychologists, and psychiatrists in the UAE. Depressive symptoms are experienced by approximately 17% to 22% of young people in the United Arab Emirates, as indicated by the International Health Policies. Depression and anxiety symptoms are reported by up to one-third of children with chronic disorders.
Based on Indication, the market is segmented into Anxiety and Depression. Based on Drugs, the market is segmented into Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Pfizer Inc.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Eli Lilly And Company
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
Market Report Segmentation
By Indication
- Anxiety
- Depression
By Drugs
- Antidepressants
- Anxiolytics
- Anticonvulsants
- Noradrenergic Agents
- Atypical Antipsychotics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Anxiety Disorders And Depression Treatment Market by Indication
Chapter 5. LAMEA Anxiety Disorders And Depression Treatment Market by Drugs
Chapter 6. LAMEA Anxiety Disorders And Depression Treatment Market by Distribution Channel
Chapter 7. LAMEA Anxiety Disorders And Depression Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Pfizer Inc.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Eli Lilly And Company
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
